Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab and Nintedanib in Advanced Solid Tumors
NCT02856425Phase 1Completed
- Sponsor
- Gustave Roussy
- Start
- Nov 2016
- Primary completion
- Jan 2025
- Modality
- Immune Checkpoint Inhibitors, Fragment-Derived Small Molecules, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label trial of pembrolizumab and nintedanib in solid tumor (9 arms), sponsored by Gustave Roussy. Primary endpoint: Maximum Tolerated Dose at 24 months. Started Nov 2016; status: completed.
02
Drugs
pembrolizumabnintedanib
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT02856425.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02856425.